Retrieve available abstracts of 279 articles: HTML format
Single Articles
April 2025
WADIA U, Moore HC, Richmond PC, Levy A, et al Effectiveness of nirsevimab in preventing RSV-hospitalisation among young
children in Western Australia 2024.
J Infect. 2025;90:106466. PubMedAbstract available
March 2025
JIN R, Qin T, Li P, Yuan J, et al Increased Circulation of Adenovirus in China During 2023-2024: Association with
an Increased Prevalence of Species B and School-Associated Transmission.
J Infect. 2025 Mar 21:106475. doi: 10.1016/j.jinf.2025.106475. PubMedAbstract available
CARSTENS G, Kozanli E, Bulsink K, McDonald S, et al Co-infection dynamics of SARS-CoV-2 and respiratory viruses in the 2022/2023
respiratory season in the Netherlands.
J Infect. 2025 Mar 21:106474. doi: 10.1016/j.jinf.2025.106474. PubMedAbstract available
PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al Post-vaccination IgG4 and IgG2 class switch associates with increased risk of
SARS-CoV-2 infections.
J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473. PubMedAbstract available
ZHAO J, Sheng G, Lyu Y, Sun Y, et al Oral ADC189 for Adults and Adolescents with Uncomplicated Influenza.
J Infect. 2025 Mar 13:106472. doi: 10.1016/j.jinf.2025.106472. PubMedAbstract available
WARD T, Paton RS, Overton CE, Mellor J, et al Understanding the Effectiveness of the Comirnaty Monovalent and Bivalent Vaccines
During the Winter Coronavirus (COVID-19) Infection Survey.
J Infect. 2025 Mar 5:106461. doi: 10.1016/j.jinf.2025.106461. PubMedAbstract available
YANG J, Zheng S, Sun J, Wu H, et al A human-infecting H10N5 avian influenza virus: clinical features, virus
reassortment, receptor-binding affinity, and possible transmission routes.
J Infect. 2025 Mar 4:106456. doi: 10.1016/j.jinf.2025.106456. PubMedAbstract available
FENG Q, Wang J, Wang X, Tian J, et al Clinical epidemiological characteristics of hospitalized pediatric viral
community-acquired pneumonia in China.
J Infect. 2025;90:106450. PubMedAbstract available
LIANG C, Begier E, Hagel S, Ankert J, et al Incidence of RSV-related hospitalizations for ARIs, including CAP: Data from the
German prospective ThEpiCAP study.
J Infect. 2025;90:106440. PubMedAbstract available
February 2025
SONG Y, Gong YN, Chen KF, Smith DK, et al Global epidemiology, seasonality and climatic drivers of the four human
parainfluenza virus types.
J Infect. 2025 Feb 26:106451. doi: 10.1016/j.jinf.2025.106451. PubMedAbstract available
MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein
COVID-19 vaccine given as a fourth dose.
J Infect. 2025 Feb 18:106447. doi: 10.1016/j.jinf.2025.106447. PubMedAbstract available
WILLIAMS KV, Krauland MG, Nowalk MP, Harrison LH, et al Increasing child vaccination coverage can reduce influenza cases across age
groups: An agent-based modeling study.
J Infect. 2025;90:106443. PubMedAbstract available
NOBLE C, McDonald E, Nicholson S, Biering-Sorensen S, et al Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.
J Infect. 2025 Feb 6:106436. doi: 10.1016/j.jinf.2025.106436. PubMedAbstract available
January 2025
QUINT JK, Dube S, Carty L, Yokota R, et al Immunocompromised individuals remain at risk of COVID-19: 2023 results from the
observational INFORM study.
J Infect. 2025 Jan 29:106432. doi: 10.1016/j.jinf.2025.106432. PubMedAbstract available
BENNETT C, Chau G, Clayton E, Chu L, et al Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated
Adolescents: A Phase 3, Randomised Trial.
J Infect. 2025 Jan 26:106428. doi: 10.1016/j.jinf.2025.106428. PubMedAbstract available
FENG S, Bibi S, Aley PK, Cappuccini F, et al Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as
a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of
BNT162b2 (COV009): A prospective cohort study.
J Infect. 2025;90:106423. PubMedAbstract available
ROMERO-RAMIREZ A, Somasundaran A, Kontogianni K, Parkes J, et al Evaluation of the diagnostic accuracy of Xpert(R) Mpox and STANDARD M10 MPX/OPX
for the detection of monkeypox virus.
J Infect. 2025 Jan 15:106413. doi: 10.1016/j.jinf.2025.106413. PubMedAbstract available
WENDEL-GARCIA PD, Ceccato A, Motos A, Franch-Llasat D, et al Empirical antibiotic therapy improves outcomes in mechanically ventilated
patients with COVID-19: An emulated targeted trial within a prospective,
multicentre cohort study.
J Infect. 2025 Jan 13:106411. doi: 10.1016/j.jinf.2025.106411. PubMedAbstract available
RJOOB K, Antonelli M, Murray B, Molteni E, et al Symptom Evolution in Individuals with Ongoing Symptomatic COVID-19 and Post
COVID-19 Syndrome After SARS-CoV-2 Vaccination Versus Influenza Vaccination.
J Infect. 2025 Jan 10:106406. doi: 10.1016/j.jinf.2024.106406. PubMedAbstract available
NURMI V, Mayne R, Knight C, Almonacid-Mendoza HL, et al Individual patient and donor seroprofiles in convalescent plasma treatment of
COVID-19 in REMAP-CAP clinical trial.
J Infect. 2025 Jan 9:106412. doi: 10.1016/j.jinf.2025.106412. PubMedAbstract available
ONG DS, Harris M, Hart JD, Russell FM, et al Lack of correlation between school reopening and trends in adult COVID-19
hospitalisations and death rates during the Delta and early Omicron periods: an
ecological analysis of five countries.
J Infect. 2025 Jan 6:106390. doi: 10.1016/j.jinf.2024.106390. PubMedAbstract available
JORDA A, Prager M, Pracher L, Haselwanter P, et al Immunogenicity, Safety, and Reactogenicity of Concomitant Administration of the
Novavax Vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent
Pneumococcal Conjugate Vaccine in Adults Aged >/=60 Years: A Randomised,
Double-blind, Placebo-contro
J Infect. 2025 Jan 3:106405. doi: 10.1016/j.jinf.2024.106405. PubMedAbstract available
December 2024
RUBIO R, Yavlinsky A, Zamudio ME, Molinos-Albert LM, et al Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2
BA.2.86 variant three years later.
J Infect. 2024 Dec 31:106402. doi: 10.1016/j.jinf.2024.106402. PubMedAbstract available
MENSAH AA, Stowe J, Brown K, LopezBernal J, et al COVID-19 reinfection in pregnancy: assessment of Severity and pregnancy outcomes
in England.
J Infect. 2024 Dec 27:106392. doi: 10.1016/j.jinf.2024.106392. PubMedAbstract available
MONK EJM, Foulkes S, Munro K, Atti A, et al Characterisation of the SARS-CoV-2 pandemic in healthcare workers within the
United Kingdom: risk factors for infection during four successive waves.
J Infect. 2024 Dec 27:106393. doi: 10.1016/j.jinf.2024.106393. PubMedAbstract available
MOK CKP, Tang YS, Tan CW, Chong KC, et al Comparison of safety and immunogenicity in the elderly after receiving either
Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine.
J Infect. 2024;90:106374. PubMedAbstract available
CITRON MP, Zang X, Leithead A, Meng S, et al Evaluation of a non-nucleoside inhibitor of the RSV RNA-dependent RNA polymerase
in translatable animals models.
J Infect. 2024;89:106325. PubMedAbstract available
ALOISIO GM, Nagaraj D, Murray AM, Schultz EM, et al Infant-derived human nasal organoids exhibit relatively increased susceptibility,
epithelial responses, and cytotoxicity during RSV infection.
J Infect. 2024;89:106305. PubMedAbstract available
November 2024
LUO H, Cui Y, Yu W, Li G, et al The impact of urbanization in China on influenza incidence across neighboring
cities.
J Infect. 2024 Nov 28:106370. doi: 10.1016/j.jinf.2024.106370. PubMedAbstract available
JIA T, Wang F, Chen Y, Liao G, et al Expanded immune imprinting and neutralization spectrum by hybrid immunization
following breakthrough infections with SARS-CoV-2 variants after three-dose
vaccination.
J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362. PubMedAbstract available
CHOW KN, Tsang YW, Chan YH, Telaga SA, et al The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic
review and meta-analysis.
J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358. PubMedAbstract available
REN Z, Yang M, Su G, Qian G, et al Real-world effectiveness and safety of Azvudine in hospitalized patients with
SARS-CoV-2 infection: a multicenter, retrospective cohort study.
J Infect. 2024 Nov 17:106355. doi: 10.1016/j.jinf.2024.106355. PubMedAbstract available
LIU Q, Zhong P, Wei Q, Wang X, et al Mechanisms of MHC-II Binding by Novel Influenza A Viruses and Their Cross-Species
Transmission Potential.
J Infect. 2024 Nov 16:106354. doi: 10.1016/j.jinf.2024.106354. PubMed
MCLEOD C, Dymock M, Flanagan KL, Plebanski M, et al The Platform Trial In COVID-19 priming and BOOsting (PICOBOO): the
immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations
administered as a second booster in BNT162b2 primed individuals aged 18-<50 and
50-<70 years old.
J Infect. 2024 Nov 14:106346. doi: 10.1016/j.jinf.2024.106346. PubMedAbstract available
HAN B, Du C, Deng M, Tang R, et al Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A
nationwide, multicenter, prospective, observational cohort study in China.
J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339. PubMedAbstract available
DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al The effect of BCG vaccination in the elderly on infectious and non-infectious
immune-mediated diseases.
J Infect. 2024;89:106344. PubMedAbstract available
HO A, McInnes N, Blunsum A, Quinn J, et al Near real-time severe acute respiratory illness surveillance characterising
influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
J Infect. 2024;89:106338. PubMedAbstract available
October 2024
WANG H, Zhou Y, Chu L, Chen K, et al Guardian-driven influenza vaccination intentions for children post-COVID-19 in
the 2024-2025 season: The positive spillover effects.
J Infect. 2024;89:106333. PubMed
KUMAR NP, Balaji S, Devi PG, Ramraj B, et al Inflammatory Cytokine Responses in Pediatric tuberculosis with or without
SARS-CoV-2 seropositivity.
J Infect. 2024 Oct 17:106314. doi: 10.1016/j.jinf.2024.106314. PubMedAbstract available
WEI X, Wang L, Li M, Qi J, et al Novel imported clades accelerated the RSV surge in Beijing, China, 2023-2024.
J Infect. 2024 Oct 17:106321. doi: 10.1016/j.jinf.2024.106321. PubMedAbstract available
MEIRMAN TD, Shapira B, Balicer RD, Rokach L, et al Trends of Common Laboratory Biomarkers after SARS-CoV-2 Infection.
J Infect. 2024 Oct 16:106318. doi: 10.1016/j.jinf.2024.106318. PubMedAbstract available
CHEN X, Meng X, Wu Q, Lim WW, et al Assessment of Neutralizing Antibody Response as a Correlate of Protection against
Symptomatic SARS-CoV-2 Infections after Administration of two doses of the
CoronaVac inactivated COVID-19 Vaccine: A Phase III Randomized Controlled Trial.
J Infect. 2024 Oct 16:106315. doi: 10.1016/j.jinf.2024.106315. PubMedAbstract available
MADSEN AMR, Gehrt L, Schaltz-Buchholzer F, Moller S, et al Evaluating the effect of BCG vaccination for non-specific protection from
infection in senior citizens during the COVID-19 pandemic: a randomised clinical
trial.
J Infect. 2024 Oct 16:106319. doi: 10.1016/j.jinf.2024.106319. PubMedAbstract available
MARCHESE AM, Fries L, Beyhaghi H, Vadivale M, et al Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly
Administered Vaccines.
J Infect. 2024 Oct 15:106317. doi: 10.1016/j.jinf.2024.106317. PubMedAbstract available
LI Y, Zhang X, Yi J, Chen Y, et al Synergistic evolution: the dynamic adaptation of SARS-CoV-2 and human protective
immunity in the real world.
J Infect. 2024 Oct 9:106310. doi: 10.1016/j.jinf.2024.106310. PubMedAbstract available
MUSCATELLO DJ, Rose N, Paul KK, Ware S, et al Epidemiological comparison of emergency department presentations with seasonal
influenza or COVID-19 and an outcome of intensive care admission or death: a
population-based records linkage study in New South Wales, Australia.
J Infect. 2024 Oct 8:106307. doi: 10.1016/j.jinf.2024.106307. PubMedAbstract available
LI Y, Sun Z, Liu X, Wei S, et al Highly Pathogenic Avian Influenza A(H5N1) Virus infection in dairy cattle:threat
of bird flu has expanded to open-air farmed livestock.
J Infect. 2024 Oct 7:106311. doi: 10.1016/j.jinf.2024.106311. PubMed
AMARILLA-IRUSTA A, Zenarruzabeitia O, Sevilla A, Sanda V, et al CD151 identifies a NK cell subset that is enriched in COVID-19 patients and
correlates with disease severity.
J Infect. 2024 Oct 5:106304. doi: 10.1016/j.jinf.2024.106304. PubMedAbstract available
FYLES M, Overton CE, Ward T, Bennett E, et al Modelling multiplex testing for outbreak control.
J Infect. 2024 Oct 1:106303. doi: 10.1016/j.jinf.2024.106303. PubMedAbstract available
September 2024
AKSU MD, van der Ent T, Zhang Z, Riza AL, et al Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19
differs from that observed in sepsis.
J Infect. 2024 Sep 30:106300. doi: 10.1016/j.jinf.2024.106300. PubMedAbstract available
DEHLIA A, Guthridge MA The persistence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
after SARS-CoV-2 infection: A systematic review and meta-analysis.
J Infect. 2024 Sep 29:106297. doi: 10.1016/j.jinf.2024.106297. PubMedAbstract available
KIRWAN PD, Foulkes S, Munro K, Sparkes D, et al Protection of vaccine boosters and prior infection against mild/asymptomatic and
moderate COVID-19 infection in the UK SIREN healthcare worker cohort: October
2023 to March 2024.
J Infect. 2024 Sep 27:106293. doi: 10.1016/j.jinf.2024.106293. PubMedAbstract available
MAZZOTTA V, Mazzaferri F, Lanini S, Mirandola M, et al Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing
drug efficacy for early treatment of COVID-19 during Omicron waves.
J Infect. 2024 Sep 27:106294. doi: 10.1016/j.jinf.2024.106294. PubMedAbstract available
BENNETT C, Hoosain Z, Koen A, Lalloo U, et al Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in
South African People Living With and Without HIV-1 Infection: A Phase 2
Randomised Trial.
J Infect. 2024 Sep 27:106285. doi: 10.1016/j.jinf.2024.106285. PubMedAbstract available
VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza
among hospitalised adults >/=65 years.
J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292. PubMedAbstract available
RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al N-protein vaccine is effective against COVID-19: phase 3, randomized,
double-blind, placebo-controlled clinical trial.
J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288. PubMedAbstract available
CHEN X, Balliew J, Bauer CX, Deegan J, et al Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD
amplicon sequencing of wastewater.
J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284. PubMedAbstract available
SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al Trends in hospitalisations for lower respiratory infections after the COVID-19
pandemic in France.
J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287. PubMedAbstract available
MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the
immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations
administered as a second booster (fourth dose) in AZD1222 primed individuals aged
50-<70 years old.
J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286. PubMedAbstract available
CHRISTENSEN J, Johansen ND, Janstrup KH, Modin D, et al Time of day for vaccination, outcomes, and relative effectiveness of high-dose
vs. standard-dose quadrivalent influenza vaccine: a post-hoc analysis of the
DANFLU-1 randomized clinical trial.
J Infect. 2024 Sep 18:106276. doi: 10.1016/j.jinf.2024.106276. PubMedAbstract available
SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al Corrigendum to "The relative vaccine effectiveness of high-dose vs standard-dose
influenza vaccines in preventing hospitalization and mortality: A meta-analysis
of evidence from randomized trials" [J Infect 89 (2024) 106187].
J Infect. 2024;89:106270. PubMed
MCDONALD E, Pittet LF, Barry SE, Bonten M, et al Antecedent and persistent symptoms in COVID-19 and other respiratory illnesses:
insights from prospectively collected data in the BRACE trial.
J Infect. 2024 Sep 6:106267. doi: 10.1016/j.jinf.2024.106267. PubMedAbstract available
CHAPMAN ME, Brendish NJ, Morris M, Spalluto CM, et al Real-world performance of a single-use, analyser-free, molecular point-of-care
test for COVID-19 used in the emergency department: results of a prospective
trial (ED-POC).
J Infect. 2024 Sep 5:106264. doi: 10.1016/j.jinf.2024.106264. PubMedAbstract available
August 2024
AZIZ AB, Sugimoto JD, Hong SL, You YA, et al Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated
household contacts in the Philippines: a cluster randomised analysis.
J Infect. 2024 Aug 30:106260. doi: 10.1016/j.jinf.2024.106260. PubMedAbstract available
GRAM MA, Thiesson EM, Pihlstrom N, Perala J, et al Comparative effectiveness of bivalent BA.4-5 or BA.1 mRNA booster vaccines among
immunocompromised individuals across three Nordic countries: A nationwide cohort
study.
J Infect. 2024;89:106261. PubMedAbstract available
HASAN T, Zhu NJ, Pearson C, Aylin P, et al Increased 30-day all-cause mortality associated with Gram-negative bloodstream
infections in England during the COVID-19 pandemic.
J Infect. 2024 Aug 29:106256. doi: 10.1016/j.jinf.2024.106256. PubMedAbstract available
HOBBS FR, Gbinigie OA, Shanyinde M, Yu LM, et al Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label,
randomised, controlled, adaptive platform trial of short- and longer-term
outcomes.
J Infect. 2024 Aug 29:106248. doi: 10.1016/j.jinf.2024.106248. PubMedAbstract available
FOULKES S, Evans J, Neill C, Bishop J, et al Prevalence and impact of persistent symptoms following SARS-CoV-2 infection among
healthcare workers: a cross-sectional survey in the SIREN cohort.
J Infect. 2024 Aug 28:106259. doi: 10.1016/j.jinf.2024.106259. PubMedAbstract available
GOTTLIEB RL, Clement M, Cook P, Deveikis A, et al The IL-6 Hypothesis in COVID-19: A Phase 2, Randomised, Double-blind,
Placebo-controlled Study to Evaluate the Efficacy and Safety of Free IL-6
Sequestration by the Monoclonal Antibody Sirukumab in Severe and Critical
COVID-19.
J Infect. 2024 Aug 23:106241. doi: 10.1016/j.jinf.2024.106241. PubMedAbstract available
LI Y, Yin Z, Wang J, Xu Y, et al Surveillance of avian influenza viruses in Hebei Province of China from 2021 to
2023: identification of a novel reassortant H3N3.
J Infect. 2024 Aug 20:106240. doi: 10.1016/j.jinf.2024.106240. PubMedAbstract available
FRYER HA, Geers D, Gommers L, Zaeck LM, et al Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in
eliciting cross-reactive memory B cells to Omicron subvariants.
J Infect. 2024 Aug 8:106246. doi: 10.1016/j.jinf.2024.106246. PubMedAbstract available
MESSINA NL, Pittet LF, McDonald E, Moore C, et al BCG vaccination of healthcare workers for protection against COVID-19: 12-month
outcomes from an international randomised controlled trial.
J Infect. 2024 Aug 8:106245. doi: 10.1016/j.jinf.2024.106245. PubMedAbstract available
WANG HI, Doran T, Crooks MG, Khunti K, et al Prevalence, risk factors and characterisation of individuals with long COVID
using Electronic Health Records in over 1.5 million COVID cases in England.
J Infect. 2024;89:106235. PubMedAbstract available
QUEK AML, Wang S, Teng O, Shunmuganathan B, et al Hybrid immunity augments cross-variant protection against COVID-19 among
immunocompromised individuals.
J Infect. 2024 Aug 7:106238. doi: 10.1016/j.jinf.2024.106238. PubMedAbstract available
SILVA-COSTA C, Gomes-Silva J, Pinho M, Friaes A, et al Rebound of pediatric invasive pneumococcal disease in Portugal after the COVID-19
pandemic was not associated with significant serotype changes.
J Infect. 2024 Aug 6:106242. doi: 10.1016/j.jinf.2024.106242. PubMedAbstract available
July 2024
LI J, Zhang Y, Liu Z, Yang Z, et al Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor
analysis in patients with hematological malignancies.
J Infect. 2024;89:106233. PubMed
BECHMAN K, Green A, Russell MD, Yang Z, et al The safety of antivirals and neutralising monoclonal antibodies used in
prehospital treatment of Covid-19.
J Infect. 2024 Jul 15:106227. doi: 10.1016/j.jinf.2024.106227. PubMedAbstract available
ANDREWS N, Osuntoki I, Stowe J, Kirsebom FCM, et al The impact of Covid-19 vaccine spring boosters on Covid-19 hospital admissions in
England 2022/23.
J Infect. 2024 Jul 10:106221. doi: 10.1016/j.jinf.2024.106221. PubMedAbstract available
KADAMBARI S, Abdullahi F, Celma C, Ladhani S, et al Epidemiological trends in viral meningitis in England: prospective national
surveillance, 2013-2023.
J Infect. 2024 Jul 8:106223. doi: 10.1016/j.jinf.2024.106223. PubMedAbstract available
STARKE KR, Kaboth P, Rath N, Reissig D, et al Cardiovascular disease risk after a SARS-CoV-2 infection: a systematic review and
meta-analysis.
J Infect. 2024 Jul 4:106215. doi: 10.1016/j.jinf.2024.106215. PubMedAbstract available
HALME ALE, Laakkonen S, Rutanen J, Nevalainen OPO, et al Short- and long-term effects of imatinib in hospitalised COVID-19 patients: A
randomised trial.
J Infect. 2024 Jul 3:106217. doi: 10.1016/j.jinf.2024.106217. PubMedAbstract available
MOKRANI D, Le Hingrat Q, Thy M, Choquet C, et al Clinical characteristics and outcomes of respiratory syncytial virus-associated
ARF in immunocompetent patients: A seven-year experience at a tertiary hospital
in France.
J Infect. 2024;89:106180. PubMedAbstract available
June 2024
BOOM TT, de Hoog MLA, Westerhof I, Jaddoe V, et al Age-specific SARS-CoV-2 transmission differed from human rhinovirus in households
during the early COVID-19 pandemic.
J Infect. 2024 Jun 29:106218. doi: 10.1016/j.jinf.2024.106218. PubMedAbstract available
BOYS R, Plank J, Bird P, Fletcher O, et al Impact of COVID-19 restrictions on the incidence of respiratory viruses in two
British Antarctic Survey bases.
J Infect. 2024;89:106196. PubMed
DU Z, Wang S, Chen R, Shan S, et al Efficacy and safety of respiratory syncytial virus prefusion F protein vaccines
in adults.
J Infect. 2024;89:106211. PubMed
CHAKA A, Pan D, Irshad M, Piranie H, et al Inclusion of racial and ethnic groups in clinical trials for COVID-19 and
post-acute COVID-19 syndrome: an analysis of studies registered on
ClinicalTrials.gov.
J Infect. 2024 Jun 20:106207. doi: 10.1016/j.jinf.2024.106207. PubMed
GONG X, Peng L, Wang F, Liu J, et al Repeated Omicron infection dampens immune imprinting from previous vaccination
and induces broad neutralizing antibodies against Omicron sub-variants.
J Infect. 2024;89:106208. PubMedAbstract available
PEREZ-GARCIA C, Sempere J, de Miguel S, Hita S, et al Surveillance of invasive pneumococcal disease in Spain exploring the impact of
the COVID-19 pandemic (2019-2023).
J Infect. 2024;89:106204. PubMedAbstract available
ZHAI K, Dong J, Zeng J, Cheng P, et al Global Antigenic Landscape and Vaccine Recommendation Strategy for Low Pathogenic
Avian Influenza A(H9N2) Viruses.
J Infect. 2024 Jun 18:106199. doi: 10.1016/j.jinf.2024.106199. PubMedAbstract available
LIU B, Xu L, Ma Y, Wang H, et al Evidence of immunity gap: Decline in antibodies against M. pneumoniae during the
COVID-19 pandemic.
J Infect. 2024 Jun 18:106209. doi: 10.1016/j.jinf.2024.106209. PubMed
KAJIHARA T, Yahara K, Kamigaki T, Hirabayashi A, et al Effects of coronavirus disease 2019 on the spread of respiratory-transmitted
human-to-human bacteria.
J Infect. 2024 Jun 17:106201. doi: 10.1016/j.jinf.2024.106201. PubMedAbstract available
MIKOLAJCZYK R, Diexer S, Klee B, Pfrommer L, et al Likelihood of Post-COVID Condition in people with hybrid immunity; data from the
German National Cohort (NAKO).
J Infect. 2024 Jun 17:106206. doi: 10.1016/j.jinf.2024.106206. PubMedAbstract available
JIANG J, Li Y, Jiang Q, Jiang Y, et al Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a
systematic review and network meta-analysis.
J Infect. 2024 Jun 2:106190. doi: 10.1016/j.jinf.2024.106190. PubMedAbstract available
PATERNINA-CAICEDO A, Quevedo DS, Rios DS, Moyano D, et al Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous
boosters for Omicron.
J Infect. 2024;88:106165. PubMed
CAI J, Lai L, Li R, Lin Q, et al The H5 subtype of avian influenza virus jumped across species to humans - a view
from China.
J Infect. 2024 Jun 1:106193. doi: 10.1016/j.jinf.2024.106193. PubMed
May 2024
SKAARUP KG, Lassen MCH, Modin D, Johansen ND, et al The relative vaccine effectiveness of high-dose vs standard-dose influenza
vaccines in preventing hospitalization and mortality: A meta-analysis of evidence
from randomized trials.
J Infect. 2024;89:106187. PubMedAbstract available
HAN B, Li XM, Li R, Ning W, et al Epidemiological Surveillance of Acute Respiratory Infections Based on Targeted
Metagenomic Next Generation Sequencing During the Flu Season after COVID-19
Pandemic in Beijing.
J Infect. 2024 May 22:106188. doi: 10.1016/j.jinf.2024.106188. PubMed
YANG X, Li X, Qiu S, Liu C, et al Global antimicrobial resistance and antibiotic use in COVID-19 patients within
health facilities: a systematic review and meta-analysis of aggregated
participant data.
J Infect. 2024 May 14:106183. doi: 10.1016/j.jinf.2024.106183. PubMedAbstract available
AMANO M, Ichikawa Y, Matsumoto S, Higashi-Kuwata N, et al Neutralization activity of HCWs' sera after Omicron XBB.1.5-adapted monovalent
COVID-19 mRNA vaccination.
J Infect. 2024;89:106179. PubMed
KIRSEBOM FCM, Stowe J, Lopez Bernal J, Allen A, et al Effectiveness of Autumn 2023 COVID-19 vaccination and residual protection of
prior doses against hospitalisation in England, estimated using a test-negative
case-control study.
J Infect. 2024 May 6:106177. doi: 10.1016/j.jinf.2024.106177. PubMedAbstract available
HALVORSEN B, Viermyr HK, Ueland T, Sagen EL, et al IL-22 is increased in hospitalized patients with COVID-19 and associates with
cardiac involvement.
J Infect. 2024 May 6:106176. doi: 10.1016/j.jinf.2024.106176. PubMed
CAINI S, Casalegno JS, Rodrigues AP, Lee V, et al Change in Age profile of Respiratory Syncytial Virus disease over the course of
annual epidemics: a multi-national study.
J Infect. 2024;88:106154. PubMedAbstract available
April 2024
CANE J, Sanderson N, Barnett S, Vaughan A, et al Nanopore sequencing of influenza A and B in Oxfordshire and the United Kingdom,
2022-23.
J Infect. 2024 Apr 29:106164. doi: 10.1016/j.jinf.2024.106164. PubMedAbstract available
CHUN JY, Jeong SJ, Kim S, Choi S, et al Performance of the Galactomannan Test for the Diagnosis of Invasive Pulmonary
Aspergillosis using Non-invasive Proximal Airway Samples.
J Infect. 2024 Apr 17:106159. doi: 10.1016/j.jinf.2024.106159. PubMedAbstract available
PINANA M, Gonzalez-Sanchez A, Andres C, Vila J, et al Genomic evolution of human respiratory syncytial virus during a decade
(2013-2023): bridging the path to monoclonal antibody surveillance.
J Infect. 2024 Apr 6:106153. doi: 10.1016/j.jinf.2024.106153. PubMedAbstract available
COLSON P, Chaudet H, Delerce J, Pontarotti P, et al Role of SARS-CoV-2 mutations in the evolution of the COVID-19 pandemic.
J Infect. 2024 Apr 1:106150. doi: 10.1016/j.jinf.2024.106150. PubMedAbstract available
March 2024
GAYLIS NB, Yang OO Understanding immune dysregulation in post-acute sequelae of COVID-19 (PASC) -
The hunt for effective treatments.
J Infect. 2024 Mar 24:106146. doi: 10.1016/j.jinf.2024.106146. PubMed
SALMAN M, Rana MS, Usman M, Tahir M, et al Re-emergence of Diphtheria after COVID-19 Pandemic in Pakistan: time to consider
booster vaccination strategies.
J Infect. 2024 Mar 19:106141. doi: 10.1016/j.jinf.2024.106141. PubMed
SUN L, Man Q, Zhang H, Xia S, et al Strong cross immune responses against sarbecoviruses but not merbecoviruses in
SARS-CoV-2 BA.5/BF.7-infected individuals with or without inactivated COVID-19
vaccination.
J Infect. 2024;88:106138. PubMed
MORENO-TORRES V, Martinez-Urbistondo M, Calderon-Parra J, de Mendoza C, et al COVID-19 Mortality Amongst the Immunosuppresed.
J Infect. 2024 Mar 11:106137. doi: 10.1016/j.jinf.2024.106137. PubMed
FATLY ZA, Betjes MGH, Dik WA, Fouchier RAM, et al Mycophenolate mofetil hampers antibody responses to a broad range of vaccinations
in kidney transplant recipients: results from a randomized controlled study.
J Infect. 2024 Mar 1:106133. doi: 10.1016/j.jinf.2024.106133. PubMedAbstract available
POWELL AA, Dowell AC, Moss P, Ladhani SN, et al Current state of COVID-19 in children: 4 years on.
J Infect. 2024 Mar 1:106134. doi: 10.1016/j.jinf.2024.106134. PubMedAbstract available
February 2024
LIU P, Cai J, Tian H, Li J, et al Intra-host genetic diversity of SARS-CoV-2 Omicron variants in children.
J Infect. 2024 Feb 29:106132. doi: 10.1016/j.jinf.2024.106132. PubMed
MEERAUS W, Joy M, Ouwens M, Taylor KS, et al AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or
frailty: the RAVEN cohort study.
J Infect. 2024 Feb 29:106129. doi: 10.1016/j.jinf.2024.106129. PubMedAbstract available
HAYWARD G, Yu LM, Little P, Gbinigie O, et al Ivermectin for COVID-19 in adults in the community (PRINCIPLE): an open,
randomised, controlled, adaptive platform trial of short- and longer-term
outcomes.
J Infect. 2024 Feb 29:106130. doi: 10.1016/j.jinf.2024.106130. PubMedAbstract available
ZHOU J, Lan L, Ai S, Lin J, et al People Living with HIV who have poor immune status are a key population for
SARS-CoV-2 prevention.
J Infect. 2024 Feb 15:106122. doi: 10.1016/j.jinf.2024.106122. PubMed
HITES M, Massonnaud CR, Jamard S, Goehringer F, et al Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with
COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled
trial.
J Infect. 2024 Feb 15:106120. doi: 10.1016/j.jinf.2024.106120. PubMed
YAO Z, Zhang L, Duan Y, Tang X, et al Molecular Insights into the Adaptive Evolution of SARS-CoV-2 Spike Protein.
J Infect. 2024 Feb 15:106121. doi: 10.1016/j.jinf.2024.106121. PubMedAbstract available
KALKERI R, Zhu M, Cloney-Clark S, Plested JS, et al Altered IgG4 Antibody Response to Repeated mRNA versus Recombinant Protein
SARS-CoV-2 Vaccines.
J Infect. 2024 Feb 13:106119. doi: 10.1016/j.jinf.2024.106119. PubMed
XIE L, Luo G, Yang Z, Wu WC, et al The clinical outcome of COVID-19 is strongly associated with microbiome dynamics
in the upper respiratory tract.
J Infect. 2024 Feb 9:S0163-4453(24)00036-7. doi: 10.1016/j.jinf.2024. PubMedAbstract available
HUNG KC, Chen IW, Sun CK Pulmonary dysfunction severity may impact optimal dexamethasone dosing in
patients with COVID-19.
J Infect. 2024 Feb 1:S0163-4453(24)00031-8. doi: 10.1016/j.jinf.2024. PubMed
January 2024
LESTON M, Elson W, Ordonez-Mena JM, Kar D, et al Disparities in COVID-19 Mortality Amongst the Immunosuppressed: A Systematic
Review and Meta-analysis for Enhanced Disease Surveillance.
J Infect. 2024 Jan 30:S0163-4453(24)00028-8. doi: 10.1016/j.jinf.2024. PubMedAbstract available
KE YK, Han XY, Lin SR, Wu HG, et al Emergence of a triple reassortment avian influenza virus (A/H5N6) from wild
birds.
J Infect. 2024 Jan 17:S0163-4453(24)00024-0. doi: 10.1016/j.jinf.2024. PubMed
MURRAY JM, Murray DD, Schvoerer E, Akand EH, et al SARS-CoV-2 Delta and Omicron community transmission networks as added value to
contact tracing.
J Infect. 2024 Jan 17:S0163-4453(24)00023-9. doi: 10.1016/j.jinf.2024. PubMedAbstract available
CORNISH EF, van der Meeren LE, van der Hoorn MP, Schoenmakers S, et al Stillbirths due to placental COVID infection associated with chronic histiocytic
intervillositis do not recur in subsequent pregnancies.
J Infect. 2024 Jan 11:S0163-4453(24)00020-3. doi: 10.1016/j.jinf.2024. PubMed
ZHANG H, Zhou K, Peng F, Gao Z, et al Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar
antiviral potency.
J Infect. 2024 Jan 6:S0163-4453(23)00600-X. doi: 10.1016/j.jinf.2023. PubMed
December 2023
ZONG K, Yuan P, Wang R, Luo Q, et al Characteristics of innate, humoral and cellular immunity in children with
non-severe SARS-CoV-2 infection.
J Infect. 2023 Dec 13:S0163-4453(23)00589-3. doi: 10.1016/j.jinf.2023. PubMedAbstract available
FERNANDEZ-DE-LAS-PENAS C, Notarte KI, Macasaet R, Velasco JV, et al Persistence of post-COVID symptoms in the general population two years after
SARS-CoV-2 infection: A systematic review and meta-analysis.
J Infect. 2023 Dec 13:S0163-4453(23)00590-X. doi: 10.1016/j.jinf.2023. PubMedAbstract available
STRAHM C, Kahlert CR, Gusewell S, Vuichard-Gysin D, et al Evolution of symptoms compatible with post-acute sequelae of SARS-CoV-2 (PASC)
after Wild-type and/or Omicron BA.1 infection: A prospective healthcare worker
cohort.
J Infect. 2023 Dec 7:S0163-4453(23)00588-1. doi: 10.1016/j.jinf.2023. PubMed
PAN D, Hui DSC, Tang JW Defining infection transmission pathways for future pandemic preparedness - An
urgent public health research priority.
J Infect. 2023;87:595-597. PubMed
AO G, Li T, Nasr B, Wang Y, et al The effect of dupilumab on clinical outcomes in patients with COVID-19: A
meta-analysis.
J Infect. 2023;87:e107-e109. PubMed
LIU Y, Sun R, Zhang H, Huang J, et al Trends and predictions of tuberculosis notification in mainland China during and
after the COVID-19 pandemic.
J Infect. 2023;87:e100-e103. PubMed
November 2023
PHAN J, Eslick GD, Elliott EJ Demystifying the global outbreak of severe acute hepatitis of unknown aetiology
in children: A systematic review and meta-analysis.
J Infect. 2023 Nov 24:S0163-4453(23)00580-7. doi: 10.1016/j.jinf.2023. PubMedAbstract available
GRAU S, Vela JM, Gurt A, Barcelo-Vidal J, et al Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild
symptomatic COVID-19 patients.
J Infect. 2023 Nov 20:S0163-4453(23)00562-5. doi: 10.1016/j.jinf.2023. PubMed
DIEP AN, Schyns J, Gourzones C, Goffin E, et al How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity
dynamics: an 18-month longitudinal study.
J Infect. 2023 Nov 17:S0163-4453(23)00558-3. doi: 10.1016/j.jinf.2023. PubMed
BRENDISH NJ, Davis C, Chapman ME, Borca F, et al Emergency Department point-of-care antiviral host response testing is accurate
during periods of multiple respiratory virus co-circulation.
J Infect. 2023 Nov 15:S0163-4453(23)00556-X. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LIECHTI FD, Bijlsma MW, Brouwer MC, van Sorge NM, et al Impact of the COVID-19 pandemic on incidence and serotype distribution of
pneumococcal meningitis - A prospective, nationwide cohort study from the
Netherlands.
J Infect. 2023 Nov 8:S0163-4453(23)00555-8. doi: 10.1016/j.jinf.2023. PubMed
HALL VJ, Insalata F, Foulkes S, Kirwan P, et al Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in
protecting against SARS-CoV-2 infections during the Delta and Omicron variant
waves; the UK SIREN cohort study September 2021 to February 2022.
J Infect. 2023 Nov 3:S0163-4453(23)00553-4. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LUNT R, Quinot C, Kirsebom F, Andrews N, et al The Impact of Vaccination and SARS-CoV-2 Variants on the Virological Response to
SARS-CoV-2 Infections during the Alpha, Delta, and Omicron waves in England.
J Infect. 2023 Nov 3:S0163-4453(23)00547-9. doi: 10.1016/j.jinf.2023. PubMedAbstract available
October 2023
BRUHN M, Obara M, Chiyyeadu A, Costa B, et al Memory B cells anticipate SARS-CoV-2 variants through somatic hypermutation.
J Infect. 2023 Oct 30:S0163-4453(23)00551-0. doi: 10.1016/j.jinf.2023. PubMed
JIANG W, Xu L, Wang Y, Hao C, et al Exploring immunity debt: Dynamic alterations in RSV antibody levels in children
under 5 years during the COVID-19 pandemic.
J Infect. 2023 Oct 29:S0163-4453(23)00550-9. doi: 10.1016/j.jinf.2023. PubMed
JIN Z, Wu J, Wang Y, Huang T, et al Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized,
double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical
trial in healthy Chinese adults.
J Infect. 2023 Oct 26:S0163-4453(23)00543-1. doi: 10.1016/j.jinf.2023. PubMedAbstract available
HA L, Levian C, Greene N, Goldfarb I, et al Association between acceptance of routine pregnancy vaccinations and COVID-19
vaccine uptake in pregnant patients.
J Infect. 2023 Oct 19:S0163-4453(23)00541-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
MARJANEH MM, Challenger JD, Salas A, Gomez-Carballa A, et al Analysis of blood and nasal epithelial transcriptomes to identify mechanisms
associated with control of SARS-CoV-2 viral load in the upper respiratory tract.
J Infect. 2023 Oct 18:S0163-4453(23)00540-6. doi: 10.1016/j.jinf.2023. PubMedAbstract available
FENWICK C, Turelli P, Duhoo Y, Lau K, et al Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and
provides full protection in monkeys.
J Infect. 2023 Oct 16:S0163-4453(23)00539-X. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LU XM, Feng XY, Wu Y, Wen CB, et al Genetic characterization of a novel H5N6 subtype highly pathogenic avian
influenza virus from goose in China.
J Infect. 2023 Oct 12:S0163-4453(23)00533-9. doi: 10.1016/j.jinf.2023. PubMed
BEARD KR, Borca F, Phan H, Brown E, et al Routine, molecular point-of-care testing for SARS-CoV-2 and other respiratory
viruses within an acute oncology service improves patient care.
J Infect. 2023 Oct 4:S0163-4453(23)00514-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
TIAN S, Liu T, Zhao XJ, Liu XL, et al Neutralization against emerging Omicron subvariants after SARS-CoV-2 reinfection.
J Infect. 2023 Oct 4:S0163-4453(23)00515-7. doi: 10.1016/j.jinf.2023. PubMed
September 2023
VELLAS C, Latour J, Tremeaux P, Ranger N, et al Molecular Evolution of Omicron Variant in Immunocompromised Individuals with
Chronic SARS-CoV-2 Infection.
J Infect. 2023 Sep 30:S0163-4453(23)00513-3. doi: 10.1016/j.jinf.2023. PubMed
ANTONELLI M, Penfold RS, Canas LDS, Sudre C, et al SARS-CoV-2 infection following booster vaccination: illness and symptom profile
in a prospective, observational community-based case-control study.
J Infect. 2023 Sep 28:S0163-4453(23)00461-9. doi: 10.1016/j.jinf.2023. PubMedAbstract available
GAO Y, Zhang Y, Mou K, Man S, et al Alterations in the outer retina and choroid in patients after COVID-19 infection.
J Infect. 2023 Sep 27:S0163-4453(23)00512-1. doi: 10.1016/j.jinf.2023. PubMed
YAMAMOTO S, Mizoue T, Konishi M, Oshiro Y, et al Kinetics and durability of nucleocapsid-specific antibodies after SARS-CoV-2
reinfection.
J Infect. 2023 Sep 26:S0163-4453(23)00511-X. doi: 10.1016/j.jinf.2023. PubMed
SNOW TAC, Arulkumaran N, Singer M, Choi SH, et al Effect of dexamethasone dose on outcomes in acute COVID-19 disease: a systematic
review and meta-analysis.
J Infect. 2023 Sep 25:S0163-4453(23)00510-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
MATSUO OM, Lindoso L, Sousa Marques HH, Polanczyk GV, et al Mental health among children and adolescents after SARS-CoV-2 infection: a
prospective study in a tertiary university hospital.
J Infect. 2023 Sep 20:S0163-4453(23)00507-8. doi: 10.1016/j.jinf.2023. PubMed
ALPIZAR SA, Accini J, Anderson DC, Eysa B, et al Molnupiravir for Intra-Household Prevention of COVID-19: the MOVe-AHEAD
Randomized, Placebo-Controlled Trial.
J Infect. 2023 Sep 8:S0163-4453(23)00500-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
CHEN JM, Tan SM, Chen RX, Gong HY, et al Distribution and risks of the infections of humans and other mammals with H5
subtype highly pathogenic avian influenza viruses in 2020-2023.
J Infect. 2023 Sep 7:S0163-4453(23)00505-4. doi: 10.1016/j.jinf.2023. PubMed
CLARK SA, Campbell H, Ribeiro S, Bertran M, et al Epidemiological and strain characteristics of invasive meningococcal disease
prior to, during and after COVID-19 pandemic restrictions in England.
J Infect. 2023 Sep 7:S0163-4453(23)00504-2. doi: 10.1016/j.jinf.2023. PubMedAbstract available
DOWELL AC, Tut G, Begum J, Bruton R, et al Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in
children but boosted by reinfection.
J Infect. 2023 Sep 1:S0163-4453(23)00465-6. doi: 10.1016/j.jinf.2023. PubMedAbstract available
August 2023
GUAN X, Huang Q, Dong M, Li M, et al SARS-CoV-2-specific antibody and T-cell immunity in convalescents after infection
wave in Beijing in late 2022.
J Infect. 2023 Aug 29:S0163-4453(23)00462-0. doi: 10.1016/j.jinf.2023. PubMedAbstract available
WHITAKER HJ, Tsang RS, Byford R, Aspden C, et al COVID-19 vaccine effectiveness against hospitalisation and death of people in
clinical risk groups during the Delta variant period: English primary care
network cohort study.
J Infect. 2023 Aug 12:S0163-4453(23)00456-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
WAGENHAUSER I, Mees J, Reusch J, Lam TT, et al Determinants of Influenza A Infection Rate in Post-COVID-19 Era.
J Infect. 2023 Aug 9:S0163-4453(23)00455-3. doi: 10.1016/j.jinf.2023. PubMed
FAUSTINI SE, Cook A, Hill H, Al-Taei S, et al Saliva antiviral antibody levels are detectable but correlate poorly with serum
antibody levels following SARS-CoV-2 infection and/or vaccination.
J Infect. 2023 Aug 3:S0163-4453(23)00439-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
July 2023
YAO XY, Lian CY, Lv ZH, Zhang XL, et al Emergence of a novel reassortant H5N6 subtype highly pathogenic avian influenza
virus in farmed dogs in China.
J Infect. 2023 Jul 26:S0163-4453(23)00386-9. doi: 10.1016/j.jinf.2023. PubMed
SUN B, Gao F Investigation of escape mechanisms of SARS-CoV-2 Omicron sub-lineages and
exploration of potential antibodies for XBB.1.
J Infect. 2023 Jul 26:S0163-4453(23)00387-0. doi: 10.1016/j.jinf.2023. PubMed
PIERANGELI A, Nenna R, Fracella M, Scagnolari C, et al Genetic diversity and its impact on disease severity in respiratory syncytial
virus subtype-A and -B bronchiolitis before and after pandemic restrictions in
Rome.
J Infect. 2023 Jul 24:S0163-4453(23)00381-X. doi: 10.1016/j.jinf.2023. PubMedAbstract available
THEODOSIOU AA, Read RC Artificial Intelligence, Machine Learning and Deep Learning: Potential Resources
for the Infection Clinician.
J Infect. 2023 Jul 17:S0163-4453(23)00379-1. doi: 10.1016/j.jinf.2023. PubMedAbstract available
KAMBOJ M, Laracy JC, Usiak S, Babady NE, et al Outcomes of hematologic malignancy patients with SARS-CoV-2 breakthrough
infections after tixagevimab-cilgavimab during community transmission of
monoclonal antibody resistant variants.
J Infect. 2023 Jul 13:S0163-4453(23)00378-X. doi: 10.1016/j.jinf.2023. PubMed
FEELISCH M, Clark AD, Cumpstey AF, Santolini J, et al Long COVID: Potential role of the Reactive Species Interactome.
J Infect. 2023 Jul 11:S0163-4453(23)00376-6. doi: 10.1016/j.jinf.2023. PubMed
RISSMANN M, Veldhuis Kroeze EJB, Tielens AGM, Rockx B, et al Influence of a chronic Schistosoma mansoni infection on the outcomes of a
SARS-CoV-2 infection in the hamster model.
J Infect. 2023 Jul 5:S0163-4453(23)00374-2. doi: 10.1016/j.jinf.2023. PubMed
BAYHAN GI, Guner R, Yahsi A, Ozkul A, et al Evaluation of the neutralizing antibody response against the omicron variant
produced by heterologous or hybrid immunity: How does the fifth dose of COVID-19
vaccine affect the neutralizing antibody response?
J Infect. 2023 Jul 4:S0163-4453(23)00369-9. doi: 10.1016/j.jinf.2023. PubMed
TAUCHER C, Lazarus R, Dellago H, Maurer G, et al Safety and Immunogenicity against Ancestral, Delta and Omicron Virus Variants
Following a Booster Dose of an Inactivated Whole-Virus COVID-19 Vaccine
(VLA2001): Interim analysis of an open-label extension of the randomized,
controlled, phase 3 COV-COM
J Infect. 2023 Jul 3:S0163-4453(23)00367-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
June 2023
VARASI I, Lai A, Fiaschi L, Bergna A, et al Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in
long-term care facility residents after the fourth dose of monovalent BNT162b2
COVID-19 vaccination.
J Infect. 2023 Jun 30:S0163-4453(23)00342-0. doi: 10.1016/j.jinf.2023. PubMed
WU JY, Hsu WH, Tsai YW, Liu TH, et al The association between zinc deficiency, and clinical outcomes of COVID-19.
J Infect. 2023 Jun 29:S0163-4453(23)00343-2. doi: 10.1016/j.jinf.2023. PubMed
DOWELL AC, Waiblinger D, Wright J, Ladhani SN, et al Nucleocapsid-Specific Antibodies as a Correlate of Protection against SARS-CoV-2
Reinfection in Children.
J Infect. 2023 Jun 28:S0163-4453(23)00340-7. doi: 10.1016/j.jinf.2023. PubMed
SU HC, Lai ZL, Chang YC, Cheng MY, et al Genomic characteristics of SARS-CoV-2 variants and their clinical impact on
patients with COVID-19 in Taiwan.
J Infect. 2023 Jun 27:S0163-4453(23)00341-9. doi: 10.1016/j.jinf.2023. PubMed
HAGIYA H, Osaki Y, Yamamoto M, Niimura T, et al Global trends of seasonal influenza-associated mortality in 2001-2018: A
longitudinal epidemiological study.
J Infect. 2023 Jun 16:S0163-4453(23)00334-1. doi: 10.1016/j.jinf.2023. PubMed
KELLY E, Greenland M, de Whalley PCS, Aley PK, et al Reactogenicity, immunogenicity and breakthrough infections following heterologous
or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A
Randomised Controlled Trial.
J Infect. 2023 Jun 16:S0163-4453(23)00330-4. doi: 10.1016/j.jinf.2023. PubMedAbstract available
STANKUNAS M, Dziugys A, Skarbalius G, Misiulis E, et al AUTHORS' REPLY TO A COMMENTARY ON THE POTENTIAL IMPACT OF COVID-19 PASSPORTS TO
EPIDEMIOLOGICAL SITUATION.
J Infect. 2023 Jun 15:S0163-4453(23)00333-X. doi: 10.1016/j.jinf.2023. PubMed
FALLET B, Foglierini M, Porret R, Alcaraz A, et al Intradermal skin test with mRNA vaccines as a surrogate marker of T cell immunity
in immunocompromised patients.
J Infect. 2023 Jun 13:S0163-4453(23)00329-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
BISHARAT N, Campisi-Pinto S Determinants of reinfection with SARS-CoV-2 Omicron variant.
J Infect. 2023 Jun 9:S0163-4453(23)00325-0. doi: 10.1016/j.jinf.2023. PubMed
CAI J, Ruan J, Lin Q, Ren T, et al China faces the challenge of influenza A virus, including H3N8, in the
post-COVID-19 era.
J Infect. 2023 Jun 7:S0163-4453(23)00324-9. doi: 10.1016/j.jinf.2023. PubMed
MOHN KG, Bredholt G, Onyango TB, Brokstad KA, et al SARS-CoV-2 infection induces long-lived B and T-cell responses up to 15 months
post-infection, irrespective of disease severity.
J Infect. 2023 Jun 7:S0163-4453(23)00302-X. doi: 10.1016/j.jinf.2023. PubMed
PASCALL DJ, Vink E, Blacow R, Bulteel N, et al Directions of change in intrinsic case severity across successive SARS-CoV-2
variant waves have been inconsistent.
J Infect. 2023 Jun 1:S0163-4453(23)00297-9. doi: 10.1016/j.jinf.2023. PubMedAbstract available
May 2023
LIU P, Cheng F, Su L, Ye Z, et al An outbreak of influenza A in Shanghai after ending the zero-COVID policy in
February-March 2023.
J Infect. 2023 May 27:S0163-4453(23)00301-8. doi: 10.1016/j.jinf.2023. PubMed
NG RW, Sze RK, Chong KC, Zhao S, et al Effectiveness of mRNA and inactivated COVID-19 vaccines: a test-negative study in
an infection-naive Hong Kong population.
J Infect. 2023 May 26:S0163-4453(23)00298-0. doi: 10.1016/j.jinf.2023. PubMedAbstract available
ZHAO T, Li Y, Xu M, Wang W, et al High proportion of H3 avian influenza virus circulating in chickens-an increasing
threat to public health.
J Infect. 2023 May 24:S0163-4453(23)00296-7. doi: 10.1016/j.jinf.2023. PubMed
FAVRESSE J, Cabo J, Douxfils J Cellular immunity against SARS-CoV-2 is predominantly boosted in vaccinated
individuals with no history of infection.
J Infect. 2023 May 19:S0163-4453(23)00292-X. doi: 10.1016/j.jinf.2023. PubMed
DIAN Y, Meng Y, Sun Y, Deng G, et al Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with
pre-existing comorbidities.
J Infect. 2023 May 17:S0163-4453(23)00290-6. doi: 10.1016/j.jinf.2023. PubMed
NAOURI D, Pham T, Dres M, Vuagnat A, et al Differences in clinical characteristics and outcomes between COVID-19 and
influenza in critically ill adult patients: a national database study.
J Infect. 2023 May 16:S0163-4453(23)00289-X. doi: 10.1016/j.jinf.2023. PubMedAbstract available
ZHONG X, Pate A, Yang YT, Fahmi A, et al The impact of COVID -19 on antibiotic prescribing in primary care in England:
evaluation and risk prediction of appropriateness of type and repeat prescribing.
J Infect. 2023 May 12:S0163-4453(23)00288-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
PINANA M, Gonzalez-Sanchez A, Andres C, Abanto M, et al The emergence, impact, and evolution of human metapneumovirus variants from 2014
to 2021 in Spain.
J Infect. 2023 May 11:S0163-4453(23)00262-1. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LV W, He J, Shao J, Chen Y, et al Causal relationships between short-chain fatty acids and L-isoleucine
biosynthesis and susceptibility and severity of COVID-19: Evidence from Mendelian
randomization.
J Infect. 2023 May 5:S0163-4453(23)00258-X. doi: 10.1016/j.jinf.2023. PubMed
GAO M, Ao G, Hao X, Xie B, et al Casirivimab-Imdevimab treatment is associated with reduced rates of mortality and
hospitalization in patients with COVID-19: A systematic review with
meta-analysis.
J Infect. 2023 May 3:S0163-4453(23)00256-6. doi: 10.1016/j.jinf.2023. PubMed
April 2023
XU J, Mao D, Liang P, Du P, et al Undetectable intrauterine transmission during the first trimester of pregnancy in
woman after COVID-19 infection.
J Infect. 2023 Apr 26:S0163-4453(23)00255-4. doi: 10.1016/j.jinf.2023. PubMed
AWAN UA, Hussain M, Qureshi M, Siddique Z, et al From COVID-19 to Measles: Prioritizing Immunization in Pakistan's Far-Flung
Regions.
J Infect. 2023 Apr 26:S0163-4453(23)00253-0. doi: 10.1016/j.jinf.2023. PubMed
ZHOU Y, Yan H, Zhou Q, Feng R, et al Impact of COVID-19 control measures on Legionella pneumophila infections in
children in Henan, China.
J Infect. 2023 Apr 26:S0163-4453(23)00254-2. doi: 10.1016/j.jinf.2023. PubMed
AZIZ NA, Nash SG, Zaidi A, Nyberg T, et al Risk of severe outcomes among SARS-CoV-2 Omicron BA.4 and BA.5 cases compared to
BA.2 cases in England.
J Infect. 2023 Apr 24:S0163-4453(23)00249-9. doi: 10.1016/j.jinf.2023. PubMed
FURUSE Y Estimation of excess cardiovascular deaths after COVID-19 in 2020.
J Infect. 2023 Apr 24:S0163-4453(23)00251-7. doi: 10.1016/j.jinf.2023. PubMed
LIU X, Munro APS, Wright A, Feng S, et al Persistence of immune responses after heterologous and homologous third COVID-19
vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect. 2023 Apr 19:S0163-4453(23)00247-5. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LUO J, Li A, Liu C, Wang Y, et al The effect of bebtelovimab on clinical outcomes in patients with COVID-19: a
meta-analysis.
J Infect. 2023 Apr 19:S0163-4453(23)00210-4. doi: 10.1016/j.jinf.2023. PubMed
WEN F, Chen G, Guo J, Guan M, et al Identification of a duck H9N2 influenza virus possessing tri-basic hemagglutinin
cleavage sites genetically close to the human H9N2 isolates in China, 2022.
J Infect. 2023 Apr 17:S0163-4453(23)00207-4. doi: 10.1016/j.jinf.2023. PubMed
PIGHI L, Henry BM, De Nitto S, Salvagno GL, et al Cellular immunity against SARS-CoV-2 depends on the serological status.
J Infect. 2023 Apr 13:S0163-4453(23)00203-7. doi: 10.1016/j.jinf.2023. PubMed
TEYSSOU E, Marot S, Gothland A, Malet I, et al SARS-CoV-2 variant-dependent inflammasome activation.
J Infect. 2023 Apr 13:S0163-4453(23)00205-0. doi: 10.1016/j.jinf.2023. PubMed
MORRISON H, Perrin F, Dedicoat M, Ahmed R, et al Impact of COVID-19 on NHS Tuberculosis Services: Results of a UK-wide survey.
J Infect. 2023 Apr 10:S0163-4453(23)00204-9. doi: 10.1016/j.jinf.2023. PubMed
SHAW RH, Greenland M, Stuart AS, Aley PK, et al Persistence of immune response in heterologous COVID vaccination schedules in the
Com-COV2 study - a single-blind, randomised trial incorporating mRNA,
viral-vector and protein-adjuvant vaccines.
J Infect. 2023 Apr 5:S0163-4453(23)00199-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
ZHAO D, Yi H, Dian Y, Meng Y, et al Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19
patients.
J Infect. 2023 Apr 3:S0163-4453(23)00200-1. doi: 10.1016/j.jinf.2023. PubMed
CHEN H, Zhang L, Zhang Y, Chen G, et al Prevalence and clinical features of long COVID from omicron infection in children
and adults.
J Infect. 2023;86:e97-e99. PubMed
March 2023
GAO Y, Luo Z, Ren S, Duan Z, et al Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized
patients with COVID-19.
J Infect. 2023 Mar 30:S0163-4453(23)00192-5. doi: 10.1016/j.jinf.2023. PubMed
KELLENI MT SARS CoV-2 Genetic Jump to a New SARS CoV-3 Pandemic: Let's Be Prepared.
J Infect. 2023 Mar 21:S0163-4453(23)00147-0. doi: 10.1016/j.jinf.2023. PubMed
NAMGUNG SH, Jung J, Kim SK, Kim EO, et al Incidence of tuberculosis infection in healthcare workers in high-risk
departments for tuberculosis after universal wearing of KF94 mask during COVID-19
pandemic.
J Infect. 2023 Mar 21:S0163-4453(23)00146-9. doi: 10.1016/j.jinf.2023. PubMed
HSU WH, Shiau BW, Tsai YW, Wu JY, et al The effect of molnupiravir on post-acute outcome of COVID-19 survivors.
J Infect. 2023 Mar 21:S0163-4453(23)00145-7. doi: 10.1016/j.jinf.2023. PubMed
DANIAL-FARRAN N, Khlaila M, Avraham-Kelbert M, Chazan B, et al Genetic Variant in Complement Receptor 1 (CR1, CD35) is Associated with A Cluster
of Severe Fatal COVID-19 in a Family.
J Infect. 2023 Mar 14:S0163-4453(23)00143-3. doi: 10.1016/j.jinf.2023. PubMed
CLARK TW, Lindsley K, Wigmosta TB, Bhagat A, et al Rapid Multiplex PCR for Respiratory Viruses Reduces Time to Result and Improves
Clinical Care: Results of a Systematic Review and Meta-Analysis.
J Infect. 2023 Mar 9:S0163-4453(23)00134-2. doi: 10.1016/j.jinf.2023. PubMedAbstract available
SHAO JW, Zhang XL, Sun J, Liu H, et al Infection of wild rats with H5N6 subtype highly pathogenic avian influenza virus
in China.
J Infect. 2023 Mar 7:S0163-4453(23)00136-6. doi: 10.1016/j.jinf.2023. PubMed
WANG H, Liu Y, Li P, Liu C, et al Emergence of epidemic variants of SARS-CoV-2 by acquiring combinations of new
highly mutable nucleotides in its genome.
J Infect. 2023 Mar 6:S0163-4453(23)00133-0. doi: 10.1016/j.jinf.2023. PubMed
QUILES-JIMENEZ A, Sousa M, Huse C, Dyrhol-Riise AM, et al Severely-ill COVID-19 patients have altered circulating levels of proteins
controlling the epitranscriptome.
J Infect. 2023 Mar 6:S0163-4453(23)00132-9. doi: 10.1016/j.jinf.2023. PubMed
SIVAKUMARAN S, Alsallakh MA, Lyons RA, Quint JK, et al Estimating the contribution of respiratory pathogens to acute exacerbations of
COPD using routine data.
J Infect. 2023;86:233-238. PubMedAbstract available
LIU P, Xu J Genomic surveillance of SARS-CoV-2 in mainland China after ending the zero-COVID
policy, December 2022 - January 2023.
J Infect. 2023 Mar 1:S0163-4453(23)00127-5. doi: 10.1016/j.jinf.2023. PubMed
February 2023
SCARPA F, Imperia E, Azzena I, Giovanetti M, et al Genetic and structural genome-based survey reveals the low potential for
epidemiological expansion of the SARS-CoV-2 XBB.1.5 sublineage.
J Infect. 2023 Feb 28:S0163-4453(23)00126-3. doi: 10.1016/j.jinf.2023. PubMed
SHAVA E, Izu A, Gaolathe T, Walker A, et al Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination
in Botswana.
J Infect. 2023 Feb 28:S0163-4453(23)00123-8. doi: 10.1016/j.jinf.2023. PubMed
DENG Y, Han S, Liu J, Guo L, et al The risks of death and hospitalizations associated with SARS-CoV-2 Omicron
declined after lifting testing and quarantining measures.
J Infect. 2023 Feb 27:S0163-4453(23)00118-4. doi: 10.1016/j.jinf.2023. PubMed
ZHOU P, Gong F, Ji T, Cao C, et al Enriched CXCR3(+) CXCR5(+) CD8(+) T cells in SARS-CoV-2 infected and vaccinated
individuals effectively respond to the antigen in recall.
J Infect. 2023 Feb 23:S0163-4453(23)00109-3. doi: 10.1016/j.jinf.2023. PubMed
GUO H, Zhao T Multiple mutations of IFITM3 are associated with COVID-19 susceptibility.
J Infect. 2023 Feb 23:S0163-4453(23)00120-2. doi: 10.1016/j.jinf.2023. PubMed
YANG F, Zhang N, Meng R, Wang K, et al Non-causal Association of COVID-19 with Systemic Lupus Erythematosus: Evidence
from a Bidirectional Mendelian RandomizationRunning title: Association of
COVID-19 with SLE.
J Infect. 2023 Feb 21:S0163-4453(23)00115-9. doi: 10.1016/j.jinf.2023. PubMed
UELAND T, Aikas LAO, Dahl TB, Gregersen I, et al Low-Density Lipoprotein Particles Carrying Proinflammatory Proteins with Altered
Aggregation Pattern Detected in COVID-19 Patients 3 Months After
HospitalizationRunning title: Low-Density Lipoprotein Particles in COVID-19
Patients.
J Infect. 2023 Feb 21:S0163-4453(23)00111-1. doi: 10.1016/j.jinf.2023. PubMed
PUTRI DU, Huang CK, Ou TY, Lin CF, et al Persistent dysregulation of cellular immunity following COVID-19 recovery despite
minimal post-COVID-19 sequelae manifestationRunning title: Occult post-COVID
immune dysregulation.
J Infect. 2023 Feb 21:S0163-4453(23)00112-3. doi: 10.1016/j.jinf.2023. PubMed
ZHANG K, Chen R, Jiang Q Allopurinol Increased the Risk of COVID-19 Hospitalization Mediated by E-Selectin
Downregulation.
J Infect. 2023 Feb 21:S0163-4453(23)00116-0. doi: 10.1016/j.jinf.2023. PubMed
MEI R, Kwok SLL, Lau EHY, Lo THK, et al Battle of Polio eradication in the Western Pacific Region in the transition to
COVID-19 endemicity.
J Infect. 2023 Feb 21:S0163-4453(23)00113-5. doi: 10.1016/j.jinf.2023. PubMed
WAN EYF, Wang B, Mathur S, Chan CIY, et al Molnupiravir and nirmatrelvir-ritonavir reduce mortality risk during post-acute
COVID-19 phase.
J Infect. 2023 Feb 21:S0163-4453(23)00117-2. doi: 10.1016/j.jinf.2023. PubMed
VALENTINI D, Carfi A, Di Paola A, Yarci-Carrion A, et al Factor associated with SARS-CoV-2 vaccination serological efficacy in adolescents
and adults with Down syndrome: data from an international, collaborative
initiative of the Trisomy 21 Research SocietyRUNNING TITLE: Factors determining
COVID-19 vaccine
J Infect. 2023 Feb 20:S0163-4453(23)00090-7. doi: 10.1016/j.jinf.2023. PubMed
POWELL AA, Ireland G, Leeson R, Lacey A, et al National and regional prevalence of SARS-CoV-2 antibodies in primary and
secondary school children in England: the School Infection Survey, a national
open cohort study, November 2021.
J Infect. 2023 Feb 15:S0163-4453(23)00085-3. doi: 10.1016/j.jinf.2023. PubMedAbstract available
BIRD PW, Pan D, Martin CA, Gogoi M, et al Awareness of HIV, Hepatitis B, Hepatitis C, Tuberculosis and COVID-19 in Migrant
Students in the UK - A Pilot Survey from an Institute of Higher Education.
J Infect. 2023 Feb 14:S0163-4453(23)00086-5. doi: 10.1016/j.jinf.2023. PubMed
ZHANG W, Sun M, Zhang P, Liang Y, et al Epidemiological characteristics of Cytomegalovirus infection in children before
and after the COVID-19 pandemic in Henan, China, 2016 - 2022.
J Infect. 2023 Feb 10:S0163-4453(23)00081-6. doi: 10.1016/j.jinf.2023. PubMed
MENG R, Zhang N, Yang F, Xu Z, et al Blood Transcriptome Analysis Revealed the Crosstalk Between Severe COVID-19 and
Systemic Lupus Erythematosus.
J Infect. 2023 Feb 10:S0163-4453(23)00080-4. doi: 10.1016/j.jinf.2023. PubMed
HSU WH, Tsai YW, Wu JY, Liu TH, et al Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for
COVID-19 survivors.
J Infect. 2023 Feb 9:S0163-4453(23)00076-2. doi: 10.1016/j.jinf.2023. PubMed
EVANS A, Qi C, Adebayo JO, Underwood J, et al Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab
on preventing hospital admission among higher-risk patients with COVID-19 in
Wales: a retrospective cohort study.
J Infect. 2023 Feb 9:S0163-4453(23)00082-8. doi: 10.1016/j.jinf.2023. PubMedAbstract available
LI L, Song X, Sun H, Ma J, et al Changes of pathogen distribution in children with wound infections before and
after the COVID-19 pandemic in Henan, China.
J Infect. 2023 Feb 9:S0163-4453(23)00079-8. doi: 10.1016/j.jinf.2023. PubMed
HU S, Zhang S, You Y, Tang J, et al Olfactory dysfunction after COVID-19; metanalysis reveals persistence in one
third of patients six months after initial infection.
J Infect. 2023 Feb 9:S0163-4453(23)00068-3. doi: 10.1016/j.jinf.2023. PubMed
LI R, Wang M, Li D, Zhang Y, et al The impact of the COVID-19 pandemic on the number of hand, foot, and mouth
disease due to enterovirus 71 infections.
J Infect. 2023 Feb 8:S0163-4453(23)00075-0. doi: 10.1016/j.jinf.2023. PubMed
CAILLARD S, Laugel E, Benotmane I, Kremer SF, et al Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant
recipients with prolonged viral shedding.
J Infect. 2023 Feb 8:S0163-4453(23)00070-1. doi: 10.1016/j.jinf.2023. PubMed
January 2023
AMANO M, Ichikawa Y, Uemura Y, Matsumoto S, et al Comparison of neutralization activity against Omicron BA.2/BA.5 in sera from HCWs
receiving heterologous/homologous COVID-19 vaccines.
J Infect. 2023 Jan 31:S0163-4453(23)00066-X. doi: 10.1016/j.jinf.2023. PubMed
LIANG J, Liu R, He W, Zeng Z, et al 70% COVID-19 infection within three weeks in the population of Macao, China.
J Infect. 2023 Jan 30:S0163-4453(23)00035-X. doi: 10.1016/j.jinf.2023. PubMed
CHANG YH, Liu TH, Wu JY, Lai CC, et al The association between corticosteroids and aspergillosis among COVID-19
patients.
J Infect. 2023 Jan 27:S0163-4453(23)00055-5. doi: 10.1016/j.jinf.2023. PubMed
RANA MS, Usman M, Alam MM, Tahir M, et al The emergence of Mumps after the COVID-19 Pandemic in Pakistan: time to consider
MMR vaccination strategies.
J Infect. 2023 Jan 26:S0163-4453(23)00057-9. doi: 10.1016/j.jinf.2023. PubMed
NISAR MI, Ansari N, Malik AA, Shahid S, et al Assessing the effectiveness of COVID-19 vaccines in Pakistan: a test-negative
case-control study.
J Infect. 2023 Jan 25:S0163-4453(23)00021-X. doi: 10.1016/j.jinf.2023. PubMed
HANI E, Bertran M, Powell A, Williams H, et al Significantly lower infection fatality rates associated with SARS-CoV-2 Omicron
(B.1.1.529) infection in children and young people: active, prospective national
surveillance, January-March 2022, England.
J Infect. 2023 Jan 24:S0163-4453(23)00037-3. doi: 10.1016/j.jinf.2023. PubMed
GENTRY CA, Nguyen P, Thind SK, Kurdgelashvili G, et al Characteristics and outcomes of US Veterans at least 65 years of age at high risk
of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
J Infect. 2023 Jan 23:S0163-4453(23)00023-3. doi: 10.1016/j.jinf.2023. PubMedAbstract available
KELLENI MT Evolution of SARS CoV-2 Omicron Subvariants BF.7 and XBB.1.5: Time to follow
Africa and abort all COVID Restrictions.
J Infect. 2023 Jan 23:S0163-4453(23)00030-0. doi: 10.1016/j.jinf.2023. PubMed
WU JY, Liu TH, Huang PY, Tsai YW, et al The effect of zinc on the outcome of patients with COVID-19: A systematic review
and meta-analysis of randomized controlled trials.
J Infect. 2023 Jan 21:S0163-4453(23)00028-2. doi: 10.1016/j.jinf.2023. PubMed
ZHAN H, Yang L, Liu Y, Li H, et al Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2
vaccine in adults with tuberculosis.
J Infect. 2023 Jan 21:S0163-4453(23)00034-8. doi: 10.1016/j.jinf.2023. PubMed
LIU X, Lv Z, Wang J, Zhou Y, et al IL1RA Mediated the Effects of Aspirin on Covid-19 severity: a Mendelian
Randomization Study.
J Infect. 2023 Jan 20:S0163-4453(23)00031-2. doi: 10.1016/j.jinf.2023. PubMed
LIANG Y, Hou L, Hou G, Zhang X, et al The influences of the COVID-19 pandemic on Epstein-Barr virus infection in
children, Henan, China.
J Infect. 2023 Jan 20:S0163-4453(23)00026-9. doi: 10.1016/j.jinf.2023. PubMed
SALTO-ALEJANDRE S, Carretero-Ledesma M, Camacho-Martinez P, Berastegui-Cabrera J, et al Serum IFN-gamma and RNAemia temporal profiles as biomarkers of severe COVID-19 in
solid organ transplant and immunocompetent patients.
J Infect. 2023 Jan 20:S0163-4453(23)00024-5. doi: 10.1016/j.jinf.2023. PubMed
KANG SW, Kim JW, Kim JY, Lim SY, et al Characteristics and risk factors of prolonged viable virus shedding in
immunocompromised patients with COVID-19: a prospective cohort study.
J Infect. 2023 Jan 19:S0163-4453(23)00029-4. doi: 10.1016/j.jinf.2023. PubMed
RANA MS, Usman M, Alam MM, Tahir M, et al Changes in the prevalence of infectious diseases before and after the COVID-19
pandemic in Pakistan.
J Infect. 2023 Jan 19:S0163-4453(23)00025-7. doi: 10.1016/j.jinf.2023. PubMed
RU X, Chen S, Zhang T, Ding Z, et al Nonpharmaceutical intervention is an effective measure to block respiratory virus
coinfections with SARS-CoV-2.
J Infect. 2023 Jan 18:S0163-4453(23)00018-X. doi: 10.1016/j.jinf.2023. PubMed
SHAH RA, Mentzer AJ, James T, Cox S, et al A novel near-patient host-protein score predicts COVID-19 deterioration at
presentation to secondary care.
J Infect. 2023 Jan 18:S0163-4453(23)00022-1. doi: 10.1016/j.jinf.2023. PubMed
KANG SW, Park H, Kim JY, Lim SY, et al Comparison of the clinical and virological characteristics of SARS-CoV-2 Omicron
BA.1/BA.2 and omicron BA.5 variants: A prospective cohort study.
J Infect. 2023 Jan 18:S0163-4453(23)00020-8. doi: 10.1016/j.jinf.2023. PubMed
LIU TH, Wu JY, Huang PY, Tsai YW, et al The effect of nirmatrelvir plus ritonavir on the long-term risk of epilepsy and
seizure following COVID-19: A retrospective cohort study including 91,528
patients.
J Infect. 2023 Jan 14:S0163-4453(23)00017-8. doi: 10.1016/j.jinf.2023. PubMed
LI X, Li T, Chen N, Kang P, et al Changes of Mycoplasma pneumoniae infection in children before and after COVID-19
pandemic in Henan, China.
J Infect. 2023 Jan 13:S0163-4453(23)00012-9. doi: 10.1016/j.jinf.2022. PubMed
DING X, Liang H, Qi X, Sun G, et al Changes of Klebsiella pneumoniae infection and carbapenem resistance in ICU
elderly infected patients before and after the COVID-19 pandemic in Zhengzhou,
China.
J Infect. 2023 Jan 9:S0163-4453(23)00009-9. doi: 10.1016/j.jinf.2023. PubMed
XU J, Wang Y, Duan G, Liu F, et al Impact of non-pharmaceutical interventions during COVID-19 pandemic on measles
and mumps in mainland China.
J Infect. 2023 Jan 9:S0163-4453(23)00008-7. doi: 10.1016/j.jinf.2023. PubMed
PATIL S, Chen H, Dong S, Liu S, et al Klebsiella pneumoniae infection in the paediatric population before and after the
COVID-19 pandemic in Shenzhen, China.
J Infect. 2023 Jan 8:S0163-4453(23)00004-X. doi: 10.1016/j.jinf.2023. PubMed
LI Y, Liang H, Ding X, Cao Y, et al Effectiveness of COVID-19 vaccine in children and adolescents with the Omicron
variant: A systematic review and meta-analysis.
J Infect. 2023 Jan 6:S0163-4453(23)00001-4. doi: 10.1016/j.jinf.2023. PubMed
YU Z, Xu S, Li L, Li M, et al Changes of Cytomegalovirus infection in neonates before and after the COVID19
pandemic in Zhengzhou, China.
J Infect. 2023 Jan 5:S0163-4453(23)00002-6. doi: 10.1016/j.jinf.2023. PubMed
ZHAO S, Sha T, Xue Y, Chen H, et al Flattening the Curve is Imperative: When China Relaxes the Dynamic Zero COVID-19
Policy.
J Infect. 2023 Jan 2:S0163-4453(22)00748-4. doi: 10.1016/j.jinf.2022. PubMed
CAMACHO J, Zulaica J, Gimenez E, Rusu L, et al Neutralizing antibodies against Omicron BA.4/5 after COVID-19 vaccination in
SARS-CoV-2 experienced versus naive individuals in the general population.
J Infect. 2023 Jan 1:S0163-4453(22)00755-1. doi: 10.1016/j.jinf.2022. PubMed
December 2022
CILLONIZ C, Motos A, Castaneda T, Gabarrus A, et al Remdesivir and survival outcomes in critically ill patients with COVID-19: A
multicentre observational cohort study.
J Infect. 2022 Dec 31:S0163-4453(22)00753-8. doi: 10.1016/j.jinf.2022. PubMed
LIANG Y, Li J, Hou L, Zhang X, et al Changes of Staphylococcus aureus infection in children before and after the
COVID-19 pandemic, Henan, China.
J Infect. 2022 Dec 28:S0163-4453(22)00751-4. doi: 10.1016/j.jinf.2022. PubMed
FERNANDEZ-DE-LAS-PENAS C, Arendt-Nielsen L, Diaz-Gil G, Gil-Crujera A, et al ACE1 rs1799752 Polymorphism is not Associated with Long-COVID Symptomatology in
Previously Hospitalized COVID-19 Survivors.
J Infect. 2022 Dec 27:S0163-4453(22)00752-6. doi: 10.1016/j.jinf.2022. PubMed
LI Y, Cao Y, Ding X, Yang D, et al Influence of the COVID-19 pandemic on Staphylococcus aureus bloodstream infection
in children, Henan, China.
J Infect. 2022 Dec 25:S0163-4453(22)00746-0. doi: 10.1016/j.jinf.2022. PubMed
SCHILDGEN O, Lusebrink J, Schildgen V Recommendation for broad use of Covid-19 mRNA vaccine boosters due to waning
vaccine effectiveness is taking the easy way out.
J Infect. 2022 Dec 24:S0163-4453(22)00744-7. doi: 10.1016/j.jinf.2022. PubMed
KRONE M, Wagenhauser I, Knies K, Hofmann D, et al Clinical accuracy of SARS-CoV-2 rapid antigen testing in screening children and
adolescents.
J Infect. 2022 Dec 21:S0163-4453(22)00740-X. doi: 10.1016/j.jinf.2022. PubMed
JANKUNAS R, Sakalauskas L, Zamaryte-Sakaviciene K, Stakisaitis D, et al COMMENTARY ON THE IMPACT OF THE COVID-19 PASSPORTS IN LITHUANIA.
J Infect. 2022 Dec 20:S0163-4453(22)00703-4. doi: 10.1016/j.jinf.2022. PubMed
C O, H W, R B, E L, et al Following the Omicron wave, the majority of children in England have evidence of
previous COVID infection.
J Infect. 2022 Dec 18:S0163-4453(22)00701-0. doi: 10.1016/j.jinf.2022. PubMed
LI X, Peng K, Cheng FW, Lam DC, et al Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine
(BNT162b2) and inactivated virus vaccine (CoronaVac).
J Infect. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022. PubMed
LIANG Y, Zhang P, Du B, Zhang X, et al Changes of Mycoplasma pneumoniae infection in children before and after the COVID
- 19 pandemic, Henan, China.
J Infect. 2022 Dec 15:S0163-4453(22)00705-8. doi: 10.1016/j.jinf.2022. PubMed
CHENG P, Li L, Sun H, Zhu C, et al Changes of pathogen distribution in children with bacterial meningitis before and
after the COVID-19 pandemic in Zhengzhou, China.
J Infect. 2022 Dec 10:S0163-4453(22)00696-X. doi: 10.1016/j.jinf.2022. PubMed
JIANG L, Tang L, Zhu L, Zhu Y, et al Viral dynamics during SARS-CoV-2 omicron infection highlight presymptomatic and
asymptomatic infectiousness.
J Infect. 2022 Dec 1:S0163-4453(22)00687-9. doi: 10.1016/j.jinf.2022. PubMed